Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Iorio A, et al. Among authors: blanchette v. Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046759 Free PMC article. Review.
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Iorio A, et al. Among authors: blanchette v. Thromb Haemost. 2017 Jun 2;117(6):1023-1030. doi: 10.1160/TH16-12-0942. Epub 2017 Mar 30. Thromb Haemost. 2017. PMID: 28357444 Review.
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Collins PW, et al. Among authors: blanchette vs. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20. J Thromb Haemost. 2009. PMID: 19143924 Free article. Clinical Trial.
The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
Sun HL, Yang M, Poon MC, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen RJ, Jackson S. Sun HL, et al. Among authors: blanchette v. Res Pract Thromb Haemost. 2021 Oct 11;5(7):e12601. doi: 10.1002/rth2.12601. eCollection 2021 Oct. Res Pract Thromb Haemost. 2021. PMID: 34667922 Free PMC article.
402 results